{"id":"NCT04060199","sponsor":"NS Pharma, Inc.","briefTitle":"Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)","officialTitle":"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-14","primaryCompletion":"2023-10-19","completion":"2023-10-19","firstPosted":"2019-08-19","resultsPosted":"2024-12-11","lastUpdate":"2024-12-11"},"enrollment":77,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Duchenne Muscular Dystrophy"],"interventions":[{"type":"DRUG","name":"Viltolarsen","otherNames":["NS-065/NCNP-01"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Viltolarsen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.","primaryOutcome":{"measure":"Change From Baseline in Time to Stand (TTSTAND) Velocity","timeFrame":"baseline, Week 13, 25, 37, 49","effectByArm":[{"arm":"Viltolarsen","deltaMin":0.026,"sd":0.0103},{"arm":"Placebo","deltaMin":0.013,"sd":0.0104}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":40,"countries":["United States","Australia","Canada","Chile","China","Greece","Hong Kong","Italy","Mexico","Netherlands","New Zealand","Norway","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["COVID-19","Pyrexia","Upper respiratory tract infection","Cough","Nasopharyngitis"]}}